Literature DB >> 2582147

Rotavirus neutralizing protein VP7: antigenic determinants investigated by sequence analysis and peptide synthesis.

P R Gunn, F Sato, K F Powell, A R Bellamy, J R Napier, D R Harding, W S Hancock, L J Siegman, G W Both.   

Abstract

The rotavirus neutralizing antigen, VP7, is a 37,000-molecular-weight glycoprotein which is a major component of the outer shell of the virion. The amino acid sequence of VP7 for strain S2 (human serotype 2) and Nebraska calf diarrhea virus (bovine serotype) has been inferred from the nucleic acid sequence of cloned copies of genomic segment nine. Comparison of the amino acid sequences of these two VP7 proteins with those already determined for other rotavirus strains reveals extensive sequence conservation between serotypes with clusters of amino acid differences sited predominantly in hydrophilic domains of the protein. Six peptides have been synthesized that span the hydrophilic regions of the molecule. Antisera to these peptides both recognize the respective homologous peptides in a solid-phase radioimmunoassay and bind to denatured VP7 in a Western blot. However, none of the antisera either recognize virus or exhibit significant neutralizing activity, indicating that these peptide sequences are not available on the surface of the virus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2582147      PMCID: PMC254866     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Letter: Synthesis of a protein with the properties of the apolipoprotein C-I (ApoLP-Ser).

Authors:  D R Harding; J E Battersby; D R Husbands; W S Hancock
Journal:  J Am Chem Soc       Date:  1976-04-28       Impact factor: 15.419

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation.

Authors:  D C Wiley; I A Wilson; J J Skehel
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

4.  The major surface glycoprotein of simian rotavirus (SA11) contains distinct epitopes.

Authors:  S Sonza; A M Breschkin; I H Holmes
Journal:  Virology       Date:  1984-04-30       Impact factor: 3.616

5.  Immunogenic structure of the influenza virus hemagglutinin.

Authors:  N Green; H Alexander; A Olson; S Alexander; T M Shinnick; J G Sutcliffe; R A Lerner
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

Review 6.  Molecular mechanisms of variation in influenza viruses.

Authors:  R G Webster; W G Laver; G M Air; G C Schild
Journal:  Nature       Date:  1982-03-11       Impact factor: 49.962

7.  Preparation and characterization of antisera to electrophoretically purified SA11 virus polypeptides.

Authors:  J W Bastardo; J L McKimm-Breschkin; S Sonza; L D Mercer; I H Holmes
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

8.  Genes of human (strain Wa) and bovine (strain UK) rotaviruses that code for neutralization and subgroup antigens.

Authors:  A R Kalica; H B Greenberg; R G Wyatt; J Flores; M M Sereno; A Z Kapikian; R M Chanock
Journal:  Virology       Date:  1981-07-30       Impact factor: 3.616

9.  A system for shotgun DNA sequencing.

Authors:  J Messing; R Crea; P H Seeburg
Journal:  Nucleic Acids Res       Date:  1981-01-24       Impact factor: 16.971

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  31 in total

1.  Specific interactions between rotavirus outer capsid proteins VP4 and VP7 determine expression of a cross-reactive, neutralizing VP4-specific epitope.

Authors:  D Y Chen; M K Estes; R F Ramig
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  Evidence for two serotype G3 subtypes among equine rotaviruses.

Authors:  G F Browning; R M Chalmers; T A Fitzgerald; D R Snodgrass
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

3.  Processing of rotavirus glycoprotein VP7: implications for the retention of the protein in the endoplasmic reticulum.

Authors:  S C Stirzaker; P L Whitfeld; D L Christie; A R Bellamy; G W Both
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

4.  A novel group A rotavirus G serotype: serological and genomic characterization of equine isolate FI23.

Authors:  G F Browning; T A Fitzgerald; R M Chalmers; D R Snodgrass
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

5.  Relation of VP7 amino acid sequence to monoclonal antibody neutralization of rotavirus and rotavirus monotype.

Authors:  B S Coulson; C Kirkwood
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Priming for rotavirus neutralizing antibodies by a VP4 protein-derived synthetic peptide.

Authors:  C F Arias; G Garcia; S Lopez
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

Review 7.  Rotavirus gene structure and function.

Authors:  M K Estes; J Cohen
Journal:  Microbiol Rev       Date:  1989-12

8.  Non-neutralizing monoclonal antibodies to a trypsin-sensitive site on the major glycoprotein of rotavirus which discriminate between virus serotypes.

Authors:  B S Coulson; K J Fowler; J R White; R G Cotton
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

9.  Marked sequence variation between segment 4 genes of human RV-5 and simian SA 11 rotaviruses.

Authors:  P Kantharidis; M L Dyall-Smith; I H Holmes
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

10.  Prevalence and genetic heterogeneity of porcine group C rotaviruses in nursing and weaned piglets in Ohio, USA and identification of a potential new VP4 genotype.

Authors:  J O Amimo; A N Vlasova; L J Saif
Journal:  Vet Microbiol       Date:  2013-02-06       Impact factor: 3.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.